Clinical Trials

Localized Renal Cancer      

Success of Active Surveillance in Patients with Untreated Small Renal Masses with the Option of Delayed Treatment
Principal Investigator: Vitaly Margulis, M.D.
Status: Recruiting
Contact: Allison Beaver, R.N.
Phone: 214-645-8789
allison.beaver@utsouthwestern.edu

Advanced MR Imaging in the Characterization of Renal Cell Carcinoma: Correlation with Pathology and Gene Expression Profiles
Principal Investigator: Ivan Pedrosa, M.D.
Status: Recruiting
Contact: Christina Carrigan, R.N.
Phone: 214-645-2704
christina.carrigan@utsouthwestern.edu

A Phase II Trial of Stereotactic Ablative Body Radiation Therapy (SABR) for Patients with Primary Renal Cancer (RCC)
Principal Investigator: Raquibul Hannan, M.D., Ph.D.
Status: Recruiting
Contact: Jean Wu, R.N., M.S.N., O.C.N. 
Phone: 214-648-1892
Jean.Wu@UTSouthwestern.edu

Safety Lead-in Phase II Trial of Neo-adjuvant SABR for IVC Tumor Thrombi in Newly Diagnosed RCC
Principal Investigator: Raquibul Hannan, M.D., Ph.D.
Status: Recruiting
Contact: Jean Wu, R.N., M.S.N., O.C.N. 
Phone: 214-648-1892
Jean.Wu@UTSouthwestern.edu 

Advanced or Metastatic Renal Cancer

Immunotherapy (IL2 and checkpoint inhibitors)

A Randomized, Open-Label, Phase III Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
Principal Investigator: James Brugarolas, M.D., Ph.D.
Status: Completed recruitment
Contact: Dendra Von Merveldt, R.N.
Phone: 214-645-8789
dendra.vonmerveldt@utsouthwestern.edu

A Phase II Trial of High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy (SABR) for Patients with Metastatic Clear Cell Renal Cell Cancer (mRCC)
Principal Investigator: Raquibul Hannan, M.D., Ph.D.
Status: Recruiting
Contact: Jean Wu, R.N., M.S.N., O.C.N.
Phone: 214-648-1892
Jean.Wu@UTSouthwestern.edu

A Phase III, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
Principal Investigator: James Brugarolas, M.D., Ph.D.
Status: Ongoing, but completed recruitment
Contact: Dendra Von Merveldt, R.N.
Phone: 214-645-8789
dendra.vonmerveldt@utsouthwestern.edu 

Phase II Randomized Trial of Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) Versus Nivolumab Alone for Metastatic Clear Cell Renal Cell Carcinoma
Principal Investigator: Raquib Hannan, M.D., Ph.D.
Status: Recruiting
Contact: Jean Wu, R.N., M.S.N., O.C.N.
Phone: 214-648-1892
Jean.Wu@UTSouthwestern.edu

Molecularly Targeted Therapies

A Phase I, Dose-Escalation Trial of PT2385 Tablets in Patients with Advanced Clear Cell Renal Cell Carcinoma
Principal Investigator: Kevin Courtney, M.D., Ph.D.
Status: Recruiting
Contact: Jenny Chang
Phone: 214-648-6551
Jenny.Chang@UTSouthwestern.edu

Phase II Randomized Trial of Pazopanib Versus Local Therapy for Renal Cell Carcinoma Patients with Limited Metastases
Principal Investigator: Raquib Hannan, M.D., Ph.D.
Status: Soon to open
Contact: Jean Wu, R.N., M.S.N., O.C.N.
Phone: 214-648-1892
Jean.Wu@UTSouthwestern.edu